Amidst the intricate tapestry of pancreatic cancer’s heterogeneity, a quartet of recurrent gene mutations has unfailingly assumed the spotlight, with KRAS, TP53, SMAD4, and CDKN2A standing as the four cardinal genes predominantly implicated [3, 6, 9]. This evidence concerns the gene CDKN2A and pancreatic neoplasm.